See also: The Week Ahead In Biotech: JPMorgan Healthcare Conference, FDA Panel Reviews Opioid Pain Drugs, I-Mab's IPO

Stocks In Focus PhaseBio Agrees To Acquire Viamet's Pipeline Assets

PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) said it has signed an agreement with Viamet Pharma and its subsidiary Selenity Pharma to buy all of the assets and intellectual property rights related to certain novel synthase inhibitors, including its lead candidate. PhaseBio said it intends to develop the asset as PB6440 for treatment-resistant hypertension.

Non-clinical IND-enabling studies are planed for 2020, which would be followed by an IND filing and a first-in-human study in early 2021.

Without disclosing specific financial terms of the deal, PhaseBio said it would make an upfront payment as well as development, approval and net sales milestones and tiered royalties on global net sales.

Last week, the stock rallied on securing a funding agreement for the development of its anticoagulant reversal agent PB2452.

The stock rallied 6.4% to $6.40 in after-hours trading.

Stemline Pre-Announces Q4, FY19 Revenue Shortfall On Soft Elzonris Sales

Stemline Therapeutics Inc (NASDAQ: STML) announced preliminary results for 2019 and said it expects Elzonris net revenue of $43.2 million for the full year and $11.8 million for the fourth quarter.

Elzonris, a CD123-targeted therapy, was approved for treating blastic plasmacytoid dendritic cell neoplasm in December 2018.

Analysts, on average, are forecasting revenue of $15.06 million for the fourth quarter and $46.44 million for the full year.

The stock was down 17.39% at $7.79 in Tuesday's premarket session.

Adaptimmune, Astellas Strike Oncology Stem Cell Therapy Partnership

Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP) shares, which skyrocketed 200% Monday on a positive data readout, could see more activity Tuesday after the company said it has signed a co-development and co-commercialization agreement with Astellas Pharma Inc. (OTC: ALPMY) for new stem-cell derived allogenic T-cell therapies for cancer.

The agreement provides for the companies identifying three targets for co-development, leveraging Adaptimmune's target identification and validation capabilities for generating T-cell receptors or TCRs, chimeric antigen receptors and HLA-independent TCRs, while also using Astellas subsidiary Universal Cell's Universal Donor Cell and Gene Editing Platform.

Amgen To Collaborate With Guardant, Qiagen On Cancer Drug Diagnostic Tests

Amgen, Inc. (NASDAQ: AMGN) announced strategic collaborations with diagnostic companies Guardant Health Inc (NASDAQ: GH) and Qiagen NV (NYSE: QGEN) to develop blood- and tissue-based companion diagnostics for its investigational cancer treatment AMG 510, a KRAS G12 inhibitor.

The companies will initially focus on companion diagnostic tests for non-small cell lung cancer, and subsequently on Amgen's other oncology clinical programs.

On The Radar Adcom Meeting

A joint meeting of the FDA's Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee will discuss Nektar Therapeutics (NASDAQ: NKTR)'s NDA for oxycodegol, a NME full mu-opioid receptor agonist, for the management of chronic low back pain in adult patients with pain severe enough to require daily, around-the-clock, long-term opioid treatment.

Related Link: Attention Biotech Investors: Mark Your Calendar For These January PDUFA Dates

0

See more from Benzinga

• A Preview Of JPMorgan's Healthcare Conference: Focus On Value-Creating Themes, 2020 Expectations

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.